Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Incarda Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsIncarda Therapeutics, Inc.

Incarda Therapeutics, Inc.

39899 Balentine Dr Ste 185, Newark, California, United States

Also known as:

incarda therapeutics

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

50.0%

Phase 2

2

25.0%

Phase 3

2

25.0%

Trial Status Distribution

Active, not recruiting

4

50.0%

Completed

3

37.5%

Terminated

1

12.5%

Clinical Trials

Trials sponsored by this organization (8)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

40 participants

A prospective, randomized, multicenter study of flecainide acetate oral inhalation solution in single and repeat dose regimens for acute conversion to sinus rhythm (SR) in subjects with recent onset of symptomatic paroxysmal atrial fibrillation (AF).

164 participants

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

Apr 202254 participants

A clinical study to investigate the efficacy of flecainide acetate inhalation solution on restoring the normal heart rhythm in patients with recent-onset, symptomatic atrial fibrillation.

Active, not recruiting

Oct 2021400 participants

A clinical study to investigate the efficacy of flecainide acetate inhalation solution on restoring the normal heart rhythm in patients with recent-onset, symptomatic atrial fibrillation.

Active, not recruiting

Oct 2021400 participants

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

May 2018176 participants

INhalation of flecainide to convert recent onset SympTomatic Atrial fibrillation to siNus rhyThm.

Active, not recruiting

Mar 2018150 participants

INhalation of flecainide to convert recent onset SympTomatic Atrial fibrillation to siNus rhyThm.

Active, not recruiting

Mar 2018150 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations